Actuate Therapeutics announced that the US Patent Office has allowed a patent for its oral tablet form of elraglusib, a drug targeting difficult-to-treat cancers. The oral tablet is designed for convenient daily dosing to sustain drug levels that enhance anti-tumor immune responses. This patent strengthens Actuate's intellectual property as it prepares to start a Phase 1/2 clinical trial in early 2027 to test safety and initial efficacy in advanced cancer patients. The oral form aims to improve patient convenience and expand treatment options, including combination therapies.
Actuate Therapeutics' recent patent allowance for its oral elraglusib tablets comes as a backdrop to the health sector's activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced US health-sector stocks, 82 rose and 47 fell today. Notable movers include ClearPoint Neuro Inc (CLPT) at USD 11.71 with a 9.54% increase and a typical hold time of 12 days, IDEXX Laboratories, Inc. (IDXX) at USD 585.99 up 6.31% with a 47-day hold, and Cassava Sciences Inc (FLNA) at USD 0.66 rising 6.11% with a 39-day hold.
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
